Brookline upgraded Intensity Therapeutics (INTS) to Buy from Hold with a $3 price target following Q2 results. Raising $11M extends the cash runway to the second half of 2026, notes the firm, which also cites the advancement of the Phase 2 triple negative breast cancer trial. The firm foresees “a favorable risk-reward as INT230-6 advances through the clinic,” the analyst tells investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS: